FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

The U.S. Food and Drug Administration has authorized the first disease-modifying treatment for Sanfilippo syndrome type A, clearing Ultragenyx Pharmaceutical to begin distributing its one-time gene therapy, Fayuvi, to specialized pediatric centers. The regulatory decision fundamentally alters the clinical landscape for the rare neurodegenerative disorder, which previously offered no approved interventions beyond supportive symptom management. Ultragenyx expects to ship the therapy to qualified treatment centers within 30 to 60 days, initiating a strict new clinical protocol that requires pediatric patients to undergo an eight-week corticosteroid regimen alongside the intravenous infusion to ensure the body accepts the viral vector.[1][2]

Sanfilippo syndrome type A, formally known in medical literature as mucopolysaccharidosis type IIIA (MPS IIIA), affects an estimated 3,000 to 5,000 patients across the developed world. The condition is driven by a specific mutation in the SGSH gene that leaves the body unable to produce sulfamidase, a crucial enzyme required for cellular waste disposal. Without sufficient levels of this enzyme, complex sugar molecules called heparan sulfate accumulate relentlessly in the lysosomes of cells, causing severe, irreversible, and progressive damage to the central nervous system as the child grows.[2][3]

The clinical trajectory of the disease is universally fatal without genetic intervention. Children typically present with progressive global developmental delay in early childhood, followed by a rapid and devastating loss of cognitive, language, and motor abilities. As the heparan sulfate continues to build up in the brain tissue, patients experience severe behavioral challenges, joint stiffness, and profound sleep disturbances, ultimately facing a median life expectancy of just 15 years. Until this week, physicians could only offer palliative care to manage these cascading symptoms as the underlying neurodegeneration advanced unchecked.[2][5]

Fayuvi, previously designated in clinical trials as UX111, utilizes a modified, non-infectious adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the SGSH gene directly into a patient's cells. Once the viral vector successfully integrates the new genetic material, the patient's own cells begin manufacturing the missing sulfamidase enzyme. This biological correction allows the body to break down the toxic heparan sulfate buildup, directly addressing the underlying mechanism of the disease rather than merely managing its downstream complications.[1][3]

"The approval of Fayuvi marks a historic moment for children and families living with MPS IIIA, which is a disease that has, until now, offered no approved treatment to alter its devastating course," Acting FDA Commissioner Kyle Diamantas stated in the September 17 announcement. Diamantas noted that the milestone reflects the agency's broader commitment to advancing gene therapies for rare pediatric conditions, emphasizing that the one-time infusion holds tremendous promise for altering the grim prognosis historically associated with the syndrome.[1]

The FDA based its approval on nearly eight years of clinical follow-up data from the Transpher A study, which tracked both biochemical marker reductions and long-term neurodevelopmental outcomes. Researchers documented substantial and durable reductions in cerebrospinal fluid heparan sulfate levels among the treated cohort, confirming that the newly introduced gene was successfully producing the necessary enzyme in the central nervous system. This sustained biochemical response provided the regulatory foundation for the agency's decision to grant standard full approval rather than an accelerated pathway.[2][5]

The biomarker improvements translated directly into tangible developmental preservation for the treated children. In the trial data submitted to regulators, eight treated children successfully reached a 36-month cognitive development age—a critical milestone that zero patients in the matched natural history cohort achieved. Furthermore, among 10 older children in later stages of the disease, researchers observed the retention of functional abilities in at least one of three key developmental areas, significantly exceeding the typical decline patterns seen in untreated patients over the same timeframe.[3][5]

Because the therapy involves systemic viral vector delivery, the FDA mandate requires administration exclusively in healthcare settings equipped to manage severe infusion reactions. Patients must begin immunosuppressive corticosteroid treatment one day prior to the infusion and continue the regimen for a minimum of eight weeks to prevent the immune system from attacking and rejecting the AAV9 vector. As with other AAV-based therapies, the FDA label carries a standard warning regarding the potential long-term risk that the inserted genetic material could integrate into the host genome and potentially lead to tumor development.[1]

Ultragenyx CEO Emil Kakkis noted that the company is now intensely focused on supporting timely access in the United States, working closely with payers and specialized treatment centers to navigate the complex logistics and high costs typical of one-time gene therapies. The authorization marks Ultragenyx's second FDA gene therapy approval in less than a month, following the recent clearance of Genglycos for glycogen storage disease type Ia, cementing the California-based biotech's position as a dominant player in the rare disease and genetic medicine sector.[2][3]

The approval also concludes a turbulent regulatory pathway for Fayuvi, which faced a complete response letter from the FDA in July 2025 over manufacturing-related issues at both Ultragenyx's Bedford, Massachusetts facility and a third-party contract manufacturer. With those production hurdles definitively cleared and the biologics license application officially approved, the immediate challenge shifts to clinical execution. Specialized pediatric centers must now prepare their infrastructure and coordinate with insurers to safely administer the first commercial doses of the therapy this fall.[3][5]